Patrick Haffey CEO Selkirk Pharma

Selkirk Pharma, a recently formed contract development and manufacturing organization, is investing $30 million for a new aseptic fill–finish facility in Washington State. Patrick Haffey, Chief Executive Officer, Selkirk Pharma, provided details of the new facility at the DCAT Week ’19 Member Company Announcement Forum, which was held March 18, 2019 in New York.

Haffey said that Selkirk Pharma was founded in 2018 to address what he described as “the insufficient supply of modern, reliable aseptic manufacturing capacity in the US.” He outlined that the facility will be housed in a new 65,000-square feet building. The sterile vial and pre-filled syringe manufacturing line will produce injectable drug products. The facility is specifically designed for contract manufacturing and will meet US Food and Drug Administration and European Medicines Agency requirements for the manufacture of commercial injectable drug products.

Initial client fills are planned for the first quarter of 2020. The facility will also house two additional manufacturing lines, details of which Haffey says will be announced at a later date.

Haffey said that the new facility will include the Variosys filling system from Bausch + Stroebel to enable production of ultra-high quality and ultra-high yield drug products. The incorporated SKAN isolator with new SKANFOG technology will provide automated, efficient decontamination and complete sterility assurance. All manufacturing process documentation and data acquisition will be fully electronic and automated.

The investment for the new facility is led by Cowles Company, of Spokane, Washington, with a consortium of other Washington State-based investors, including Arnold Venture Group.

.